Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Non-Randomized, Single-Arm, Phase 1/2 Study of Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

NCT06585514 is registered in ClinicalTrials.gov with Beijing GoBroad Hospital as lead sponsor.

NCT NCT06585514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Non-Randomized, Single-Arm, Phase 1/2 Study of Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Lead sponsor
Beijing GoBroad Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 17, 2024
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis (ln), systemic lupus erythematosus (sle)